Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Paroxetine impurity a
Drug ID BADD_D01682
Description Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others.[T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters.[A31914] Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class.[A31914] The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Indications and Usage Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder.[L3358] One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause.[L7703] Off-label, paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome (IBS).[A1093,A181754,A181904]
Marketing Status approved; investigational
ATC Code N06AB05
DrugBank ID DB00715
KEGG ID D02362; D05374; D02260
MeSH ID D017374
PubChem ID 3038120
TTD Drug ID D06GDY
NDC Product Code 13107-157; 61919-512; 61919-658; 62135-544; 63629-3349; 70518-3518; 72241-029; 72241-031; 13107-156; 58118-0183; 62135-425; 63187-105; 69367-336; 72241-030; 55289-972; 68071-1740; 68180-646; 68180-647; 68382-099; 62135-426; 63187-564; 69367-335; 70518-0003; 70518-3277; 70518-3613; 72189-492; 50268-643; 60760-501; 62135-427; 62135-543; 68382-098; 68788-7410; 69117-0026; 70518-3430; 0574-0279; 71610-056; 62135-542; 63187-434; 68180-645; 68788-6870; 69117-0024; 70954-319; 71209-094; 71335-0321; 0615-8174; 61919-322; 61919-596; 69117-0025; 71209-096; 71335-0544; 43353-713; 43547-409; 63629-1840; 63739-963; 68382-097; 69117-0027; 70518-2465; 70518-2574; 71209-095; 0615-8173; 13107-155; 50268-640; 62135-541; 68382-001; 69367-337; 0615-8359; 80425-0339; 50268-642; 60760-398; 63187-190; 63739-888; 13107-154
UNII AT4YDK3T53
Synonyms Paroxetine | Aropax | BRL-29060 | BRL 29060 | BRL29060 | FG-7051 | FG 7051 | FG7051 | Paroxetine Acetate | Seroxat | Paroxetine Hydrochloride Anhydrous | Paroxetine Maleate | Paroxetine, cis-(+)-Isomer | Paroxetine, cis-(-)-Isomer | Paroxetine, trans-(+)-Isomer | Paxil | Paroxetine Hydrochloride Hemihydrate | Paroxetine Hydrochloride, Hemihydrate | Paroxetine Hydrochloride
Chemical Information
Molecular Formula C19H21NO3
CAS Registry Number 112058-81-8
SMILES C1CNCC(C1C2=CC=CC=C2)COC3=CC4=C(C=C3)OCO4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acute coronary syndrome02.02.02.015; 24.04.04.011---
Musculoskeletal stiffness15.03.05.027---
Musculoskeletal discomfort15.03.04.001---
Inappropriate antidiuretic hormone secretion05.03.03.001; 14.05.07.001---
Affect lability19.04.01.001---
Transaminases increased13.03.04.036---
Faecaloma07.01.03.004---
Faecalith07.01.03.007---
Bipolar disorder19.16.01.003---
Female sexual dysfunction19.08.05.001; 21.03.02.004---
Major depression19.15.01.003---
Nuchal rigidity15.05.04.005; 17.05.02.006---
Vasodilation procedure25.03.01.001---
Disturbance in sexual arousal19.08.04.003---
Blood alkaline phosphatase increased13.04.02.004--
Urine output increased13.13.03.002---
Mental disorder19.07.01.002---
Porphyrin metabolism disorder03.08.01.006; 09.01.10.004; 14.14.01.006---
Decreased appetite08.01.09.028; 14.03.01.005--
Erectile dysfunction19.08.04.001; 21.03.01.007--
Reproductive tract disorder21.10.05.006---
Ill-defined disorder08.01.03.049---
Psychotic disorder19.03.01.002--
Congenital genitourinary abnormality03.06.02.002; 20.08.03.001; 21.15.02.002---
Increased bronchial secretion22.12.01.002---
Urethritis noninfective20.07.02.002---
Cystitis noninfective20.03.02.001--
Vulvovaginal mycotic infection11.03.05.004; 21.14.02.004---
Ulcerative keratitis06.04.02.004; 10.02.01.021--
Hyperpathia17.02.07.015---
The 13th Page    First    Pre   13 14    Next   Last    Total 14 Pages